

May 3rd, 2023



Pfizer Inc.
66 Hudson Blvd.
New York, NY 10011

Subject: Supply Alert: CAVERJECT® (alprostadil) Dual Chamber Syringe [20µg] – Supply Disruption

Dear Health Care Provider:

This is to inform you that Pfizer is experiencing a significant supply disruption with Caverject® Dual Chamber devices 20µg in the US. In addition, Caverject 20mcg vials are currently in stock out with potential supply replenishment mid-2024. Caverject® 40mcg vials, package of 6, remain available for patients, but it is estimated that this dosage could be in a stock out situation in June of 2023 with potential recovery by mid-2024. This supply disruption is due to an unforeseen shortage of a hormone deficiency medicine produced by a competitor, which has led to unprecedented demand and significant need for a Pfizer drug, also an essential medicine to treat a hormone deficiency in children and adults.

We understand this is disappointing news for Caverject® Dual Chamber users. We are actively evaluating alternative options to re-start manufacture of Caverject® Dual Chamber as soon as possible, including manufacture at alternative sites. Information on the shortage is published on the FDA.com website.

Patients are advised to consult with their healthcare professional about alternate treatment options available that may be suitable.

Please refer to the Prescribing Information for further details

<https://labeling.pfizer.com/ShowLabeling.aspx?id=667>

<https://labeling.pfizer.com/ShowLabeling.aspx?id=590>

For additional medical questions on Caverject®, please contact Pfizer Medical Information 1-800-438-1985.

Reporting Adverse Events

Healthcare providers are encouraged to report adverse events, including product defects, by contacting Pfizer at 1-800-438-1985 or by contacting the FDA at <http://www.fda.gov/Safety/MedWatch> or by calling 1-800-FDA-1088.

Sincerely,
Local Medical Lead

(c) 2023 Pfizer Inc. All rights reserved.